CTLA4 and neoplasm: In another similar study, the neutralization of soluble NKG2D ligands such as MICA and MICB with mAb B10G5 was effective against prostate cancer and its metastases, leading to increased infiltration with NK cells to tumor parenchyma and improving CTLA-4 blockade therapy [229].